Zevra Therapeutics (ZVRA) announced the completion of an agreement to sell its Rare Pediatric Disease Priority Review Voucher or PRV for $150 million.
The voucher was granted to Zevra following the FDA approval of Miplyffa or Arimoclomol, a treatment for the neurological manifestations of Niemann-Pick disease type C.
This sale is expected to close within 30 to 45 days, pending customary closing conditions.
The non-dilutive capital from the sale will support the company's continued investment in the commercial launches of MMiplyffa and Olpruva, as well as advancing its pipeline for rare disease treatments.
Zevra said the sale will strengthen its balance sheet and position the company for continued success in the rare disease space.
ZVRA closed Wednesday's (Feb.26 2025) trading at $7.39 up by 0.41 percent. In premarket trading Thursday the stock is up by 8.24 percent at $8.00 on the Nasdaq.
For comments and feedback: editorial@rttnews.com